Funds and ETFs Incyte Corporation

INCY

US45337C1027

Name	Weight	AuM	1st Jan change	Investor Rating
RAREVIEW SYSTEMATIC EQUITY ETF - USD	0.02%	45 M€	0.00%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.02%	306 M€	+6.29%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	39 M€	+6.43%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.01%	105 M€	+3.80%	-
RH TACTICAL ROTATION ETF - USD	0.01%	12 M€	+15.09%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	17 M€	+3.36%	-
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD	0.01%	17 M€	+5.97%	-
ASYMMETRIC SMART ALPHA S&P 500 ETF - USD	0.01%	1 M€	-.--%
GOOSE HOLLOW TACTICAL ALLOCATION ETF - USD	0.01%	32 M€	+3.08%	-
AMUNDI INDEX MSCI NORTH AMERICA ESG BROAD CTB UCITS ETF DR (C) - EUR	0.01%	322 M€	+13.88%	-
AMUNDI INDEX MSCI NORTH AMERICA ESG BROAD CTB UCITS ETF DR (D) - EUR	0.01%	29 M€	-.--%	-
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.01%	34 M€	+4.49%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	0.01%	54 M€	+0.99%	-
IQ REAL RETURN ETF - USD	0.01%	6 M€	+3.89%
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	8 M€	+0.94%	-
STRATEGY SHARES NASDAQ 5HANDL INDEX ETF - USD	0.01%	2 M€	+3.16%	-
LYXOR MSCI USA ESG BROAD CTB (DR) UCITS ETF - ACC - EUR	0.01%	414 M€	+13.07%	-
LYXOR MSCI USA ESG BROAD CTB (DR) UCITS ETF - DIST - EUR	0.01%	1,006 M€	-.--%	-
STRATEGY SHARES NASDAQ 7HANDL INDEX ETF - USD	0.01%	756 M€	+1.02%	-
NEXT FUNDS S&P 500 ETF - JPY HEDGED	1.20%	129 M€	+8.27%	-

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-06-12 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.19 USD

Average target price

73.35 USD

Spread / Average Target

+28.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-8.92%	12.84B
CSL LIMITED	-3.15%	89.69B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	41.34B
BIOGEN INC.	-10.51%	33.72B
UCB	+58.75%	26.11B
BIOMARIN PHARMACEUTICAL INC.	-20.09%	14.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.46%	11.66B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.05%	11.52B
SWEDISH ORPHAN BIOVITRUM AB	+4.72%	8.92B
INNOVENT BIOLOGICS, INC.	-10.64%	8.38B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
57.19 ^USD	+0.16%		-0.71%	-8.92%

May. 15	Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM
May. 13	Equities Close Mixed as Markets Weigh Consumer Inflation Survey	MT